Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| AL ALGSAligos Therapeutics Inc. | $6.67+3.6% | $41.7M | 6 assetsPhase 2 | Pevifoscorvir sodium (ALG-000184)Phase 2 · Data readout | |
| AL ALKSAlkermes plc | $48.33+0.6% | $8.11B | 7 assetsPhase 2 |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| AL ALLKAllakos Inc | $0.33+0.0% | $29.7M | 6 assetsStage unavailable | No dated catalyst |
| AL ALLOAllogene Therapeutics | $2.09-0.5% | $722.1M | 7 assetsPhase 2 | ALLO-329 [CD19/CD70 Dual CAR]Phase 1 · Data readout |
| AL ALLRAllarity Therapeutics | $1.42-0.7% | $22.6M | 3 assetsStage unavailable | No dated catalyst |
| AL ALMSAlumis | $24.17+5.7% | $3.13B | 5 assetsPhase 2b | ESK-001Phase 2b · Data readout |
| AL ALNYAlnylam Pharmaceuticals | $236.22+3.0% | $31.61B | 18 assetsPhase 2 | Mivelsiran (ALN-APP) Phase 2 · Data readout |
| AL ALPNAlpine Immune Sciences | $64.97+0.0% | $4.46B | 5 assetsStage unavailable | No dated catalyst |
| AL ALTAltimmune Inc. | $3.11+5.4% | $605.0M | 9 assetsPhase 3 | Pemvidutide (ALT-801) (GLP-1R/GCGR)Phase 2 · Data readout |
| AL ALVOAlvotech | $4.43+3.7% | $1.50B | 8 assetsPDUFA | AVT05 (Proposed Biosimilar to Simponi® & Simponi Aria® (golimumab))PDUFA · Approval decision |
| AL ALVRAllovir Inc | $4.15+0.7% | — | 5 assetsStage unavailable | No dated catalyst |
| AL ALXOALX Oncology Holdings Inc | $2.04+2.5% | $282.1M | 13 assetsPhase 2 | ALX2004Phase 1 · Data readout |
| AL ALZNAlzamend Neuro | $1.56-4.3% | $7.5M | 6 assetsPhase 2 | AL001Phase 1/2 · Data readout |
| AM AMAMAmbrx Biopharma | $28.00+0.0% | — | 2 assetsStage unavailable | No dated catalyst |
| AM AMGNAmgen | $439.33+1.9% | $237.52B | 42 assetsStage unavailable | No dated catalyst |
| AM AMLXAmylyx Pharmaceuticals | $38.66-2.5% | $4.31B | 8 assetsStage unavailable | No dated catalyst |
| AM AMPEAmpio Pharmaceuticals Inc | $0.18+0.0% | $207,884 | 2 assetsStage unavailable | No dated catalyst |
| AM AMPHAmphastar Pharmaceuticals | $21.60-0.4% | $918.8M | 3 assetsStage unavailable | No dated catalyst |
| AM AMRNAmarin Corporation | $14.09+0.2% | $297.6M | 3 assetsStage unavailable | No dated catalyst |
| AM AMRXAmneal Pharmaceuticals Inc. | $17.91+0.1% | $6.24B | 15 assetsApproved | No dated catalyst |
| AM AMTIApplied Molecular Transport Inc. | $0.26+0.0% | — | 5 assetsStage unavailable | No dated catalyst |
| AM AMYTAmryt Pharma | $14.70+0.0% | — | 3 assetsStage unavailable | No dated catalyst |
| AN ANABAnaptyBio Inc | $57.74+1.9% | $1.71B | 16 assetsPDUFA | Imsidolimab (ANB019) (anti-IL-36R)PDUFA · Approval decision |
| AN ANEBAnebulo Pharmaceuticals | $0.33-5.7% | $13.5M | 2 assetsStage unavailable | No dated catalyst |
| AN ANGNAngion Biomedica | — | — | 4 assetsStage unavailable | No dated catalyst |
| AN ANIKAnika Therapeutics | $21.78+2.1% | $291.5M | 2 assetsStage unavailable | No dated catalyst |
| AN ANIXAnixa Biosciences | $3.71+3.3% | $126.2M | 2 assetsStage unavailable | No dated catalyst |
| AN ANLAdlai Nortye Biopharma | $13.70-0.1% | $882.3M | 7 assetsPhase 2 | AN4005 (PD-L1 Inhibitor)Phase 1 · Data readout |
| AN ANNXAnnexon Inc. | $5.07-2.1% | $961.2M | 8 assetsPhase 3 | ANX1502Phase 1a · Data readout |
| AN ANROAlto Neuroscience | $34.28+0.1% | $1.35B | 6 assetsPhase 2b | ALTO-300Phase 2b · Data readout |
| AN ANTXAN2 Therapeutics | $5.81+0.3% | $219.2M | 5 assetsPhase 2 | Epetraborole (LeuRS Inhibitor)Phase 2 · Data readout |
| AN ANVSAnnovis Bio | $1.82+1.7% | $77.5M | 2 assetsPhase 3 | Buntanetap (ANVS401)Phase 3 · Data readout |
| AP APGEApogee Therapeutics | $134.75+0.0% | $10.20B | 8 assetsPhase 1b | APG279 (APG777 + APG990)Phase 1b · Data readout |
| AP APL SApellis Pharmaceuticals | — | — | 11 assetsStage unavailable | No dated catalyst |
| AP APLMApollomic Inc | $24.33+3.2% | $70.5M | 4 assetsStage unavailable | No dated catalyst |
| AP APLTApplied Therapeutics | $0.10+0.0% | $14.9M | 6 assetsStage unavailable | No dated catalyst |
| AP APREAprea Therapeutics | $0.64+1.2% | $8.1M | 5 assetsPhase 1 | APR-1051Phase 1 · Data readout |
| AP APTOAptose Biosciences | $1.71+0.0% | — | 3 assetsStage unavailable | No dated catalyst |
| AP APVOAptevo Therapeutics | $2.68-2.8% | $4.8M | 2 assetsPhase 1/2 | Mipletamig (APVO436) +/- Venetoclax + AzacitidinePhase 1/2 · Data readout |
| AQ AQSTAquestive Therapeutics | $4.66+3.7% | $584.9M | 9 assetsStage unavailable | No dated catalyst |